Vaxart (NASDAQ: VXRT)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vaxart Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vaxart Company Info
Vaxart, Inc
News & Analysis
Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.
Learn about the companies that are manufacturing COVID-19 vaccines and what you should know before investing in coronavirus vaccine stocks.
These players may change the world of medicine.
The company still is far from the vaccine race finish line.
The similarities are striking.
These stocks are all about cutting-edge technology.
The past 12 months have been difficult for the biotech stock.
Vaxart is winning in two crucial areas.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/06/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.